About This Desk

What Research Peptides US is

Research Peptides US is an independent editorial reference desk covering five compounds that dominate US research-peptide conversation for different reasons: BPC-157 (tissue repair), KPV (gut inflammation), NAD+ (cellular energy and longevity), retatrutide (investigational metabolic triple-agonist), and tirzepatide (approved dual-agonist, the lead compound here). The organizing idea is blunt by design: sort what the published literature actually shows from what a supplier's landing page or a forum thread claims.

These five sit at genuinely different points on the same evidence ladder, and that's precisely why they're grouped together. Reading them side by side — rather than one at a time on five different vendor sites — makes the gap between hype and evidence maturity impossible to miss. Tirzepatide has a full FDA-approved, multi-trial record. Retatrutide has strong Phase 2 numbers and zero approvals. NAD+ has solid human dosing trials but unproven downstream benefit. BPC-157 has one two-person human safety pilot on top of decades of rat data. KPV has no human trial data whatsoever. This desk treats all five with the same editorial discipline, whatever stage they're actually at.

How it is compiled

Three rules govern everything on this site.

First, every specific claim is tied to a numbered citation. Percentages, trial sizes, half-lives, and dose figures all trace to a peer-reviewed journal article, a registered clinical trial publication, or a peer-reviewed clinical-reference chapter, collected on the references page with DOIs and PubMed links where available.

Second, evidence is described at the strength it actually has. A finding from a 338-person Phase 2 trial is labeled as exactly that — not extrapolated into a universal claim. A rat study stays a rat study. Community-reported effects are explicitly labeled anecdotal and never attached to a specific dose.

Third, the five compound pages are cross-referenced. Because themes recur across compounds — receptor mechanisms, GI side effects, gray-market sourcing risk, the gap between animal and human data — the pages link to one another and to the comparison page, so readers can follow a theme across the whole desk rather than reading one compound in isolation.

What it is not

Research Peptides US is not a pharmacy, a clinic, a telehealth platform, or a vendor of any kind. It doesn't sell, source, or broker any compound discussed here, and it has no affiliate relationship with any research-chemical supplier, pharmaceutical company, or telehealth provider. It doesn't diagnose conditions, prescribe anything, or recommend a dose, schedule, or route of administration for any person.

Tirzepatide is an approved prescription medicine available only through a licensed provider. Retatrutide is investigational and legally available only inside registered clinical trials. BPC-157 and KPV are unregulated research chemicals with no approved human use. NAD+ and its precursors are supplements or compounded products, not FDA-approved drugs. Readers seeking clinical guidance should consult a licensed healthcare provider. Editorial correspondence on citation corrections or newly published research can go through the contact page — this desk cannot respond to requests for medical advice.